Which drug stops joint damage best in early psoriatic arthritis?
NCT ID NCT07486843
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a TNF inhibitor (adalimumab biosimilar) is better than methotrexate at preventing bone damage in people with early psoriatic arthritis. About 108 adults with active disease and symptoms for less than 2 years will be randomly assigned to one of the two drugs. Researchers will use a special 3D scan to measure joint damage at the start, 24 weeks, and 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Methotrexate or adalimumab biosimilar (Amgevita)
What this could lead to
If it works, this could show which treatment better prevents permanent joint damage in early psoriatic arthritis.
What could go wrong
This is a small, early-phase trial (108 people) comparing two existing drugs, so results may not apply to everyone. Both drugs have known side effects like infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS (PSA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Chinese University of Hong Kong, Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••